左旋门冬酰胺酶联合方案治疗外周T细胞淋巴瘤疗效观察

Clinical effect of L-asparaginase in the treatment of peripheral T-cell lymphoma

目的:评价含左旋门冬酰胺酶(L-ASP)化疗方案治疗外周T细胞淋巴瘤(PTCL)的疗效。方法:初治T细胞淋巴瘤患者27例,L-ASP组15例接受联合化疗(LOD),对照组12例接受不含L-ASP的LOD。比较两组的有效率和2年生存率。结果:有效率(完全缓解加部分缓解)L-ASP组为73.3%,对照组为25%(P<0.05)。1年生存率L-ASP组57.4%,2年生存率43.1%,对照组1年生存率21.2%,2年生存率为0(P<0.05)。L-ASP治疗的不良反应主要表现为白细胞减少和胃肠道反应。结论:L-ASP为主的化疗方案可能提高PTCL的疗效和1年、2年生存率,不良反应可耐受。

Objective：To study the clinical efficacy of L-asparaginase（L-ASP） chemotherapy in the treatment of peripheral T cell lymphoma（PTCL）.Methods： In this study,27 cases of diagnosed T cell lymphoma patients were divided into two groups： L-ASP group（15 cases） and CHOP group（12 cases）.The L-ASP group was treated with LOD chemotherapy containing L-ASP and the CHOP group was treated with combined chemotherapy without L-ASP.The effective rate and 2-year＇s survival rate were compared between the two groups.Results：The effective rate（including complete and partial anesis） of L-ASP group was 73.3%,and the CHOP group was 25 %（P0.05）.The 1-year＇s survival rate and 2-year＇s survival rate of L-ASP group and CHOP group were 57.4%,43.1%;21.2%,0%,respectively.The main side-effects of the LOD chemotherapy with L-ASP were mainly neutropenia and gastrointestinal reactions.Conclusion：L-ASP based chemotherapy may improve the efficacy of PTCL,increase 1-year＇s and 2-year＇s survival rate with tolerable side-effect.